Paper24252885
Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS and 1 other. Pediatr Res, 2014. Cited by 54 papers, by iCite.
Cite this record
ConductScience Library. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Papers, record 24252885. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24252885
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anemia, Sickle Cell | Major topic |
| Antisickling Agents | Major topic |
| Hydroxyurea | Major topic |
| Age Factors | |
| Animals | |
| Child | |
| Child, Preschool | |
| Fetal Hemoglobin | |
| Genetic Markers | |
| Genetic Predisposition to Disease | |
| Humans | |
| Infant | |
| Infant, Newborn | |
| Phenotype | |
| Polymorphism, Single Nucleotide | |
| Risk Factors | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| UL1 RR024156 | NCRR NIH HHS | United States | UL1RR024156 | PubMed and NIH |
| 5UL1RR024156 | NCRR NIH HHS | United States | UL1RR024156 | PubMed and NIH |
Source NIH RePORTER
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6200161 | Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? | Blood | 1984 | https://conductscience.org/library/papers/6200161 | PubMed |
| 2 | 23861242 | Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. | Am J Hematol | 2013 | https://conductscience.org/library/papers/23861242 | PubMed |
| 3 | 21921042 | Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. | Blood | 2011 | https://conductscience.org/library/papers/21921042 | PubMed |
| 4 | 22517797 | Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. | Pediatr Blood Cancer | 2012 | https://conductscience.org/library/papers/22517797 | PubMed |
| 5 | 22130804 | Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. | Blood | 2012 | https://conductscience.org/library/papers/22130804 | PubMed |
| 6 | 21157349 | Update on fetal hemoglobin gene regulation in hemoglobinopathies. | Curr Opin Pediatr | 2011 | https://conductscience.org/library/papers/21157349 | PubMed |
| 7 | 21372708 | Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? | Curr Opin Hematol | 2011 | https://conductscience.org/library/papers/21372708 | PubMed |
| 8 | 22833547 | Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. | Blood | 2012 | https://conductscience.org/library/papers/22833547 | PubMed |
| 9 | 17313560 | Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. | Eur J Haematol | 2007 | https://conductscience.org/library/papers/17313560 | PubMed |
| 10 | 21068435 | Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. | Blood | 2011 | https://conductscience.org/library/papers/21068435 | PubMed |
| 11 | 20513116 | The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. | Am J Hematol | 2010 | https://conductscience.org/library/papers/20513116 | PubMed |
| 12 | 23125209 | Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications. | Am J Physiol Heart Circ Physiol | 2013 | https://conductscience.org/library/papers/23125209 | PubMed |
| 13 | 8822914 | Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. | Blood | 1996 | https://conductscience.org/library/papers/8822914 | PubMed |
| 14 | 20230905 | Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. | Mutat Res | 2010 | https://conductscience.org/library/papers/20230905 | PubMed |
| 15 | 21057501 | Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. | Nat Genet | 2010 | https://conductscience.org/library/papers/21057501 | PubMed |
| 16 | 22294512 | Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. | Pediatr Blood Cancer | 2012 | https://conductscience.org/library/papers/22294512 | PubMed |
| 17 | 17993617 | Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. | Blood | 2008 | https://conductscience.org/library/papers/17993617 | PubMed |
| 18 | 19914165 | Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. | Cell | 2009 | https://conductscience.org/library/papers/19914165 | PubMed |
| 19 | 2001460 | The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients. | Blood | 1991 | https://conductscience.org/library/papers/2001460 | PubMed |
| 20 | 3539223 | Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. | Blood | 1987 | https://conductscience.org/library/papers/3539223 | PubMed |
Cited by40
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41375813 | When Blood Disorders Meet Cancer: Uncovering the Oncogenic Landscape of Sickle Cell Disease. | J Clin Med | 2025 | https://conductscience.org/library/papers/41375813 | PubMed |
| 40868933 | Role of OCT1 and MAP3K5 Genetic Polymorphisms in Hydroxyurea Pharmacokinetics. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40868933 | PubMed |
| 40268903 | Exploring pharmacogenetic factors influencing hydroxyurea response in tanzanian sickle cell disease patients: a genomic medicine approach. | Pharmacogenomics J | 2025 | https://conductscience.org/library/papers/40268903 | PubMed |
| 39695103 | Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39695103 | PubMed |
| 39624343 | A Comparative Analysis of Hydroxyurea Treatment on Coagulation Profile Among Sickle Cell Anaemia Children in Lagos, Nigeria. | Adv Hematol | 2024 | https://conductscience.org/library/papers/39624343 | PubMed |
| 39552261 | Impact of hydroxycarbamide treatment on the whole-blood transcriptome in sickle cell disease. | Br J Haematol | 2025 | https://conductscience.org/library/papers/39552261 | PubMed |
| 39487201 | Computational screening of phytochemicals present in some Nigerian medicinal plants against sickle cell disease. | Sci Rep | 2024 | https://conductscience.org/library/papers/39487201 | PubMed |
| 39359845 | Advancing life: innovative approaches to enhance survival in sickle cell anemia patients. | Ann Med Surg (Lond) | 2024 | https://conductscience.org/library/papers/39359845 | PubMed |
| 39211422 | Effects of Hydroxyurea Treatment on Haemolysis in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania. | Tanzan J Sci | 2021 | https://conductscience.org/library/papers/39211422 | PubMed |
| 39026269 | Towards genomic medicine: a tailored next-generation sequencing panel for hydroxyurea pharmacogenomics in Tanzania. | BMC Med Genomics | 2024 | https://conductscience.org/library/papers/39026269 | PubMed |
| 37269388 | Sickle cell disease and acute leukemia: one case report and an extensive review. | Ann Hematol | 2023 | https://conductscience.org/library/papers/37269388 | PubMed |
| 36060689 | Sickle cell cerebrovascular reactivity to a CO2 stimulus: Too little, too slow. | Front Physiol | 2022 | https://conductscience.org/library/papers/36060689 | PubMed |
| 36047926 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. | Cochrane Database Syst Rev | 2022 | https://conductscience.org/library/papers/36047926 | PubMed |
| 35784862 | Effects of Hydroxyurea on Skeletal Muscle Energetics and Function in a Mildly Anemic Mouse Model. | Front Physiol | 2022 | https://conductscience.org/library/papers/35784862 | PubMed |
| 34857507 | Guidelines on sickle cell disease: primary stroke prevention in children and adolescents. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines project: Associação Médica Brasileira - 2021. | Hematol Transfus Cell Ther | 2022 | https://conductscience.org/library/papers/34857507 | PubMed |
| 34090531 | Genome-based therapeutic interventions for β-type hemoglobinopathies. | Hum Genomics | 2021 | https://conductscience.org/library/papers/34090531 | PubMed |
| 33936317 | Laser tweezers as a biophotonic tool to investigate the efficacy of living sickle red blood cells in response to optical deformation. | Biophys Rev | 2021 | https://conductscience.org/library/papers/33936317 | PubMed |
| 33567814 | Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia. | Haematologica | 2022 | https://conductscience.org/library/papers/33567814 | PubMed |
| 32563256 | High fetal hemoglobin level is associated with increased risk of cerebral vasculopathy in children with sickle cell disease in Mayotte. | BMC Pediatr | 2020 | https://conductscience.org/library/papers/32563256 | PubMed |
| 32461799 | Hemoglobinopathies in Iran: An Updated Review. | Int J Hematol Oncol Stem Cell Res | 2020 | https://conductscience.org/library/papers/32461799 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24252885
GET https://conductscience.org/api/papers/v1/24252885/references?page=2